alpha-melanocyte stimulating hormone
α-Melanocyte-stimulating hormone (α-MSH) is an endogenous peptide hormone and neuropeptide of the melanocortin family, with a tridecapeptide structure and the amino acid sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. It is the most important of the melanocyte-stimulating hormones (MSHs) (also known as melanotropins) in stimulating melanogenesis, a process that in mammals (including humans) is responsible for pigmentation primarily of the hair and skin. It also plays a role in feeding behavior, energy homeostasis, sexual activity, and protection against ischemia and reperfusion injury. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 1999 (NCT00004496)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNA mismatch repair protein Msh2Supplementation
MSH2 supplementation
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaΑ-Melanocyte-stimulating hormone ↗
- WikipediaAlpha-Melanocyte-stimulating hormone ↗
Also known as
- 581-05-5
- alpha-melanocyte stimulating hormone
- alpha-melanocyte stimulating hormone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004496 | Phase 1 | Feb 1, 1999 | The University of Texas, Dallas |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 1999 |